Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders

ISBN-13: 9780128165454 / Angielski / Twarda / 2019 / 372 str.

Benjamin Bonavida; Lucia Morbidelli

Spis treści

I. Applications of Nitric Oxide in Cancer1. Nitric Oxide-Releasing Engineered Nanoparticles: Tools for Overcoming Drug Resistance in Chemotherapy2. Reversal of Multiple Cancer Oncogenic Pleiotropic Properties by NO-modulating Therapies3. Antitumor Effect of a Metal Nonoate Through Angiogenesis Impairment4. Therapeutic Implications of the Nitric Oxide Pathway in the Angiogenesis of Tumors and Inflammatory-Related Disorders5. Nitric oxide and cancer: To inhibit or to induce iNOS - That is the Question?6. Arginine Metabolism Regulates Nitric Oxide Production in Melanoma Tumor Microenvironment to Provide Survival Advantage to Tumor Cells7. Cancer and Beyond: Discovery and Development of NO-releasing Therapeutics8. Nitric Oxide Scavenging-Based Therapies for Targeting Colorectal Cancer9. Therapeutic Aspects of Protein Denitrosylation10. Nitric Oxide-Releasing Functional Nanomaterials for Anticancer Therapy

II. Applications of Nitric Oxide in Inflammatory-Related Disorders11. The Role of Nitric Oxide on Vascular Dysfunction During Aging and Alzheimer's Disease12. Carbonic Anhydrase Inhibitor - NO Donor Hybrids and Their Pharmacologic Applications13. Understanding the Roles of Nitric Oxide During Sepsis, an Inflammatory Disorder14. Nanoporous Materials: New Generation of Nitric Oxide Donors

III. Abstracts (Presentations at Conference in Siena, October 4th-5th, 2018)A. Serum Nitric Oxide Metabolites and The Incidence of Metabolic Syndrome and Its Phenotypes: A Population-Based Prospective StudyB. Nitric Oxide (NO): A Multifaceted Target for Reversal of Cancer Cell Pleiotropic Properties by NO-modulating TherapiesC. Pharmacology of Hepatoselective Nitric Oxide - Donors in NAFLD in MiceD. New NO-Releasing Doxorubicins as Targeted Therapy Against Chemoresistance in Castration-resistant Prostate Cancer: In Vitro and In Vivo EvaluationsE. Anticancer Effect of a Novel H2S-Hybrid Molecule on Human Breast Adenocarcinoma (MFC-7) and Human Breast Epithelial (MCF-10A) Cell LinesF. Heme Oxygenase-1 In Duchenne Muscular Dystrophy: Interaction with Nitric Oxide Synthase Pathway in Satellite Cells DifferentiationG. In Vitro Assessment of NitDox Toxicity Towards VasculatureH. The Regulation of GSNOR Expression Discloses the Role of S-nitrosylation in Aging and DiseaseI. Effects of Long-term Nitrite Supplementation on Gene Expressions of GLUT2, GLUT4 and Glucokinase in Male Obese Type 2 Diabetic RatsJ. Nitric Oxide Re-Instates Doxorubicin Cytotoxic and Pro-Immunogenic Effects in Refractory Breast CancerK. Anti-Cancer Activities of Erucin a H2S-donor Isothiocyanate from Eruca Sativa Mill.: Is H2S the Real Player?L. Hydrogen Sulfide as a Signaling Molecule in The Cardiovascular System: Actions and Interactions with NOM. Nitric Oxide in Cancer Resistance to Cisplatin: Tumor Associated Macrophages as Key Players.N. Therapeutic Potential of Nitric Oxide Modulation in Ocular Diseases: A Focus on Novel NO-Releasing MoleculesO. Pro-Apoptotic Effects of S-Nitrosothiols O-Chloro and M-Chloro S-Nitroso-Aryl-Amides in Human Breast Cancer Cell LinesP. Light Guided Production of Nitric Oxide and Singlet Oxygen for the Multi-Modal Treatment of CancerQ. Potential for Chemoprevention with Nitric Oxide- and Hydrogen Sulfide-Releasing DrugsR. H2S Metabolism in Colon Cancer Cells Exposed to Hypoxia

O autorze

Dr. Morbidelli's experience is within the molecular and biochemical pharmacology of angiogenesis and microcirculation and its biological application in diseases and cancer. Through of a plethora of in vitro and in vivo models, she has contributed to the characterization of the pro- and antiangiogenic activities of designed synthetic molecules and natural products and their potential applications in angiogenesis-dependent diseases of the cardiovascular system, ocular disorders, neurovascular diseases and cancer. She co-organized with Professor Bonavida the Fourth International Workshop on "Nitric Oxide in Cancer” held in Sevilla in March 13-14, 2015. The meeting addressed different topics such as NO, mutagenesis, carcinogenesis, tumor promotion and tumor growth; NO regulation of cell death pathways; NO and proliferation and epithelial-mesenchymal transition; Regulation of immune response by NO; Antitumoral activity of NO-based releasing strategies: pre-clinical studies; Antitumoral activity of NO-based releasing strategies: clinical trials. Benjamin Bonavida, PhD, has been involved in the field of immunology and cancer biology for several decades and has published extensively in the fields of cancer resistance, chemotherapy, immunotherapy, and various molecular approaches to circumvent the resistance of the cancer cells using sensitizing agents. Accordingly, he was the first to publish a book on tumor sensitization in 2008. More recently, Dr. Bonavida is the Series Editor of 3 series published by Elsevier/Academic Press ("Cancer Sensitizing Agents for Chemotherapy,” "Breaking Cancer Resistance to Therapeutic Antibodies,” and "Breaking Tolerance to Anti-Cancer Immunotherapy”) and several books have been published and many are in development. He has published extensively in the field of NK biology and cytotoxicity in the past, and many of these publications were in collaboration with the co-editor Dr. Anahid Jewett.